Skip to content
ChickenStockChickenStock
ResearchDYN
Dyne Therapeutics logo

Dyne Therapeutics (DYN) stock

NASDAQ

$16.02-4.07%(-0.68)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-4.94x

Net loss — not comparable

P/B

3.22x

P/S

—

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Operating income decreased from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 5, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

23 SEC filings
  • Cox JohnCEO & President · Nov 13, 2026Open-market sale5,513 shares · $93K
    Avg. price $16.82351,994 shares held after
  • Kerr DouglasHead of R&D and CMO · Nov 13, 2026Open-market sale2,604 shares · $44K
    Avg. price $16.82167,960 shares held after
  • Lucera ErickChief Financial Officer · Nov 13, 2026Open-market sale1,991 shares · $33K
    Avg. price $16.82117,775 shares held after
  • Friedl-Naderer JohannaChief Commercial Officer · Nov 13, 2026Open-market sale231 shares · $4K
    Avg. price $16.82152,666 shares held after
  • Kerr DouglasHead of R&D and CMO · Oct 20, 2026Grant or award8,000 shares · $0
    Avg. price $0170,564 shares held after
  • Posner Brian SDirector · Oct 2, 2026Open-market purchase2,500 shares · $40K
    Avg. price $1627,000 shares held after
  • Cox JohnCEO & President · Sep 8, 2026Open-market sale5,658 shares · $107K
    Avg. price $18.88357,507 shares held after
  • Kerr DouglasChief Medical Officer · Sep 8, 2026Open-market sale1,290 shares · $24K
    Avg. price $18.88162,564 shares held after
  • Friedl-Naderer JohannaChief Commercial Officer · Sep 8, 2026Open-market sale185 shares · $3K
    Avg. price $18.88152,897 shares held after
  • Kerr DouglasChief Medical Officer · Sep 4, 2026Open-market sale3,745 shares · $91K
    Avg. price $24.35163,854 shares held after
  • Friedl-Naderer JohannaChief Commercial Officer · Sep 4, 2026Open-market sale900 shares · $22K
    Avg. price $24.35153,082 shares held after
  • Rhodes Jason PDirector · Aug 14, 2026Open-market sale2,160,516 shares · $54.0M
    Avg. price $25
    Show 3 price lots
    • 1,359,674 shares × $25$34.0M
    • 478,377 shares × $25$12.0M
    • 322,465 shares × $25$8.1M
  • Rhodes Jason PDirector · Aug 13, 2026Open-market sale426,412 shares · $11.2M
    Avg. price $26.2
    Show 3 price lots
    • 268,354 shares × $26.2$7.0M
    • 94,415 shares × $26.2$2.5M
    • 63,643 shares × $26.2$1.7M
  • Cox JohnCEO & President · Aug 13, 2026Open-market sale4,986 shares · $131K
    Avg. price $26.28363,165 shares held after
  • Lucera ErickChief Financial Officer · Aug 13, 2026Open-market sale1,797 shares · $47K
    Avg. price $26.28119,766 shares held after
  • Kerr DouglasChief Medical Officer · Aug 13, 2026Open-market sale1,556 shares · $41K
    Avg. price $26.28167,599 shares held after
  • Friedl-Naderer JohannaChief Commercial Officer · Aug 13, 2026Open-market sale226 shares · $6K
    Avg. price $26.28153,982 shares held after
  • Kersten DirkDirector · Jul 27, 2026Open-market sale261,460 shares · $6.7M
    Avg. price $25.5135
    Show 2 price lots
    • 256,072 shares × $25.5024$6.5M
    • 5,388 shares × $26.0428$140K

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Dyne Therapeutics (DYN) stock information

NASDAQ

Dyne Therapeutics (DYN) is listed on NASDAQ. Its market capitalization is about $3B. On trailing-twelve-month earnings the P/E ratio is -4.94, and the P/B ratio is 3.22. Return on equity is -65.1%. These figures are computed in-house from official filings and are reference information only.

Dyne Therapeutics — frequently asked questions

What is the P/E ratio of Dyne Therapeutics (DYN)?
On a trailing-twelve-month basis, DYN trades at a P/E ratio of -4.94. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Dyne Therapeutics?
DYN has a market capitalization of about $3B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.